Evidence map›Paper›PMID 39090252›Full record

ArticleScientific reports2024

Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models.

Hasan Hüseyin Hendek, Alina Blusch, Neele Heitmann, Sarah Oberhagemann, Seray Demir, Xiomara Pedreiturria, Ralf Gold, Simon Faissner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hasan Hüseyin HendekDepartment of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Gudrunstr. 56, 44791, Bochum, Germany.
Alina BluschDepartment of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Gudrunstr. 56, 44791, Bochum, Germany.
Neele HeitmannDepartment of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Gudrunstr. 56, 44791, Bochum, Germany.
Sarah OberhagemannDepartment of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Gudrunstr. 56, 44791, Bochum, Germany.
Seray DemirDepartment of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Gudrunstr. 56, 44791, Bochum, Germany.
Xiomara PedreiturriaDepartment of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Gudrunstr. 56, 44791, Bochum, Germany.
Ralf GoldDepartment of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Gudrunstr. 56, 44791, Bochum, Germany.
Simon FaissnerDepartment of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Gudrunstr. 56, 44791, Bochum, Germany. simon.faissner@rub.de.

Funding

Avicenna-Studienwerk e.V. Stipend for HHHMedical Faculty of Ruhr-University Bochum F981-R2020Medical Faculty of Ruhr-University Bochum Research funds from the faculty for the Department of Neurology
6 · The paper itself

Abstract

So far, only a small number of medications are effective in progressive multiple sclerosis (MS). The sphingosine-1-phosphate-receptor (S1PR)-1,5 modulator siponimod, licensed for progressive MS, is acting both on peripheral immune cells and in the central nervous system (CNS). So far it remains elusive, whether those effects are related to the neurotrophin brain derived neurotrophic factor (BDNF). We hypothesized that BDNF in immune cells might be a prerequisite to reduce disease activity in experimental autoimmune encephalomyelitis (EAE) and prevent neurotoxicity. MOG

Indexed as

AzetidinesBenzyl CompoundsBrain-Derived Neurotrophic FactorEncephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisAnimalsDisease Models, AnimalFemaleMiceMice, Inbred C57BLMice, KnockoutSphingosine 1 Phosphate Receptor ModulatorsSpinal CordAzetidinesBdnf protein, mouseBenzyl CompoundsBrain-Derived Neurotrophic FactorsiponimodSphingosine 1 Phosphate Receptor ModulatorsBrain derived neurotrophic factorExperimental autoimmune encephalomyelitisMultiple sclerosisNeuroinflammationNeuroprotectionSiponimod

Identifiers

PMID39090252
PMCPMC11294562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.